Thus, we conducted a systematic review and meta-analysis of the qualifying literature aiming to assess the incidence and nature of irAEs resulting from the use of anti-PD-1 or anti-PD-L1 antibodies to treat NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.